RadNet Inc
RDNT
ISIN null / Valor 2812237
RadNet Inc
UMushroom community rating:
About company
RadNet Inc. is a leading provider of outpatient diagnostic imaging services in the United States, operating over 365 freestanding, fixed-site centers. The company offers a comprehensive range of imaging services, including MRI, CT, PET/CT, mammography, ultrasound, and X-ray. RadNet's IT division, eRAD, specializes in delivering integrated, web-based, cloud solutions designed to streamline medical imaging workflows. Additionally, RadNet Television (RTV) provides targeted programming for patients and their families, enhancing the overall patient experience. The company's extensive network and advanced technological solutions position it as a significant player in the medical imaging industry.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (19.11.2025):
RadNet Inc reported robust financial results for the second quarter of 2025, achieving record quarterly revenue and Adjusted EBITDA. The company’s total revenue climbed 8.4% year-over-year to $498.2 million while Adjusted EBITDA grew by 12.3% to $81.2 million. Enhanced performance in the Digital Health segment—with revenue up 30.9% to $20.7 million—and increased advanced imaging volumes contributed to the strong results, prompting an upward revision to full-year 2025 revenue and EBITDA guidance.
Record Revenue and EBITDA
In Q2 2025, RadNet Inc achieved a quarterly record with total company revenue of $498.2 million, an 8.4% increase compared to Q2 2024. Adjusted EBITDA also reached a new high at $81.2 million, marking a 12.3% year-over-year improvement.
Digital Health Segment Growth
The Digital Health reportable segment delivered significant gains, with revenue rising by 30.9% to a record $20.7 million and Adjusted EBITDA increasing by 4.1% to $3.4 million compared to the same quarter in 2024, underscoring the expansion in digital initiatives and AI-backed solutions.
Improved Margins and Operational Progress
Adjusted EBITDA margins improved by 57 basis points to 16.3% in Q2 2025 alongside notable increases in advanced imaging procedures, including a 9.0% growth in MRI volumes and advancements across CT and PET/CT modalities.
Upward Guidance Revision
Buoyed by these positive trends and sustainable growth in both imaging and digital health, RadNet Inc has revised its full-year 2025 guidance upward for revenue and Adjusted EBITDA, reflecting enhanced confidence in its operational and financial performance.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
6403 M
Market cap (USD)
1,162,356
Daily traded volume (Shares)
71.58 / 69.51
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
